Taisho Makes Tender Offer For Biofermin In Proposed Japanese Merger
This article was originally published in PharmAsia News
Executive Summary
Japan's Taisho Pharmaceutical made a tender offer to acquire Biofermin Pharmaceutical for an amount that could reach $251.4 million. The Taisho offer is for up to 62 percent of Biofermin's outstanding shares. Taisho plans to turn Biofermin, which sells both prescription and over-the-counter drugs, into a subsidiary as part of an effort to strengthen the buyer's development of drugs and food products. Biofermin and its largest shareholder approve of the takeover. (Click here for more - a subscription may be required